ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL

Abstract

This clinical trial is a pre-surgical Phase IIb, randomized, double-blind, multi-centric study for postmenopausal patients with histologically confirmed ER-positive breast cancer (Stage 0-II) comparing the Exemestane standard dose regimen versus two alternative, less frequent dose regimens. The clinical trial will address alternate dosing of Exemestane results in non-inferior reductions in serum estradiol.

Key facts

NIH application ID

10261308

Project number

261201200034I-P00005-26100008-1

Recipient

UNIVERSITY OF TX MD ANDERSON CAN CTR

Principal Investigator

POWEL BROWN

Activity code

N01

Funding institute

NIH

Fiscal year

2020

Award amount

$12,938

Award type

—

Project period

2015-08-01 → 2021-07-31